Mitochondrial Quality Control as a Therapeutic Target.

dc.contributor.author

Suliman, Hagir B

dc.contributor.author

Piantadosi, Claude A

dc.contributor.editor

Mattson, Mark P

dc.coverage.spatial

United States

dc.date.accessioned

2017-04-12T13:10:27Z

dc.date.available

2017-04-12T13:10:27Z

dc.date.issued

2016-01

dc.description.abstract

In addition to oxidative phosphorylation (OXPHOS), mitochondria perform other functions such as heme biosynthesis and oxygen sensing and mediate calcium homeostasis, cell growth, and cell death. They participate in cell communication and regulation of inflammation and are important considerations in aging, drug toxicity, and pathogenesis. The cell's capacity to maintain its mitochondria involves intramitochondrial processes, such as heme and protein turnover, and those involving entire organelles, such as fusion, fission, selective mitochondrial macroautophagy (mitophagy), and mitochondrial biogenesis. The integration of these processes exemplifies mitochondrial quality control (QC), which is also important in cellular disorders ranging from primary mitochondrial genetic diseases to those that involve mitochondria secondarily, such as neurodegenerative, cardiovascular, inflammatory, and metabolic syndromes. Consequently, mitochondrial biology represents a potentially useful, but relatively unexploited area of therapeutic innovation. In patients with genetic OXPHOS disorders, the largest group of inborn errors of metabolism, effective therapies, apart from symptomatic and nutritional measures, are largely lacking. Moreover, the genetic and biochemical heterogeneity of these states is remarkably similar to those of certain acquired diseases characterized by metabolic and oxidative stress and displaying wide variability. This biologic variability reflects cell-specific and repair processes that complicate rational pharmacological approaches to both primary and secondary mitochondrial disorders. However, emerging concepts of mitochondrial turnover and dynamics along with new mitochondrial disease models are providing opportunities to develop and evaluate mitochondrial QC-based therapies. The goals of such therapies extend beyond amelioration of energy insufficiency and tissue loss and entail cell repair, cell replacement, and the prevention of fibrosis. This review summarizes current concepts of mitochondria as disease elements and outlines novel strategies to address mitochondrial dysfunction through the stimulation of mitochondrial biogenesis and quality control.

dc.identifier

https://www.ncbi.nlm.nih.gov/pubmed/26589414

dc.identifier

68/1/20

dc.identifier.eissn

1521-0081

dc.identifier.uri

https://hdl.handle.net/10161/13988

dc.language

eng

dc.publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

dc.relation.ispartof

Pharmacol Rev

dc.relation.isversionof

10.1124/pr.115.011502

dc.subject

Carbon Monoxide

dc.subject

Erythropoietin

dc.subject

Estrogens

dc.subject

Free Radical Scavengers

dc.subject

Heme Oxygenase-1

dc.subject

Humans

dc.subject

Hydrogen Sulfide

dc.subject

Inflammasomes

dc.subject

Inflammation

dc.subject

Inflammation Mediators

dc.subject

Mitochondria

dc.subject

Mitochondrial Degradation

dc.subject

Mitochondrial Diseases

dc.subject

Nitric Oxide

dc.subject

Oxidative Phosphorylation

dc.subject

Polyphenols

dc.subject

Thyroid Hormones

dc.title

Mitochondrial Quality Control as a Therapeutic Target.

dc.type

Journal article

pubs.author-url

https://www.ncbi.nlm.nih.gov/pubmed/26589414

pubs.begin-page

20

pubs.end-page

48

pubs.issue

1

pubs.organisational-group

Anesthesiology

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke

pubs.organisational-group

Duke Cancer Institute

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Medicine

pubs.organisational-group

Medicine, Pulmonary, Allergy, and Critical Care Medicine

pubs.organisational-group

Pathology

pubs.organisational-group

School of Medicine

pubs.publication-status

Published

pubs.volume

68

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
suliman-hagir-mitochondrial-quality-control-as-a-therapeutic-target.pdf
Size:
1.31 MB
Format:
Adobe Portable Document Format